Shares of PTC Therapeutics Inc. PTCT, -10.35% were down 10.1% in trading on Wednesday morning, the day after the company said enrollment in a Phase 2 clinical trial for its Huntington’s disease treatment candidate has been paused. PTC told investors on Tuesday night that the Food and Drug Administration had requested additional information about the study. The company said there were no adverse events reported at trials in the U.S. and in other sites being conducted in other countries. PTC’s stock is up 14.3% this year, while the broader S&P 500 SPX, -1.27% is down 21.9%.
